Ipsen Group Overview
- Founded
- 1929
- Status
- Public
- Employees
- 5,807
- Stock Symbol
- IPN
- Investments
- 23
- Share Price
- $88.95
- (As of Tuesday Closing)
Ipsen Group General Information
Description
Ipsen SA is a specialty and generic drug manufacturing company. The company's main therapeutic areas include oncology, endocrinology, neurosciences, and primary care. Ipsen maintains two segments: specialty care and primary care. The company derives most of its sales from the specialty care segment, with a vast majority of sales being generated in Western European countries. Ipsen's research and development strategy focus on peptides and toxins. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Contact Information
Primary Industry
Other Commercial Services
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
PAR
Primary Office
- 65, quai Georges Gorse
- 92100 Boulogne Billancourt
- France
+33 01 00 00 00 00
Ipsen Group Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $88.95 | $85.74 | $37.48 - $113.19 | $7.36B | 82.7M | 126K | -$0.65 |
Ipsen Group Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
|---|---|---|---|---|
| EV | 7,554,844 | 8,328,283 | 10,595,811 | 10,047,191 |
| Revenue | 2,993,342 | 3,014,329 | 2,771,268 | 2,268,724 |
| EBITDA | 181,810 | 129,296 | 757,957 | 546,402 |
| Net Income | (54,079) | (56,756) | 459,636 | 307,090 |
| Total Assets | 4,757,128 | 4,824,469 | 3,863,418 | 3,685,486 |
| Total Debt | 1,106,450 | 955,843 | 383,894 | 434,532 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Ipsen Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Ipsen Group‘s full profile, request access.
Request a free trialIpsen Group Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Ipsen SA is a specialty and generic drug manufacturing company. The company's main therapeutic areas include oncology, e
Other Commercial Services
Boulogne Billancourt, France
5,807
As of 2019
00000
00000000000
00000
00000000
reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaeca
000000000000000
Leiden, Netherlands
000
As of 0000
00000
000000000
00000
00000000
quat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla p
000000000000000
Milan, Italy
0000
As of 0000
0.000
0000-00-00
000000000000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialIpsen Group Competitors (37)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pharming Group | Formerly VC-backed | Leiden, Netherlands | 000 | 00000 | 000000000 | 00000 |
| 000000000 | Private Equity-Backed | Milan, Italy | 0000 | 000000000000 | ||
| 000000 00000000000 | Corporation | Parma, Italy | 0000 | |||
| 000000 | Corporation | Paris, France | 000000 | 000000000000 | ||
| 00000 000000000000 | Private Equity-Backed | Atlanta, GA | 000 | 000.00 | 0&0 |
Ipsen Group Executive Team (27)
Ipsen Group Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000 00000000 | Ipsen Group | Board Member | 000 0000 |
| 00000 0000 | Ipsen Group | Chief Executive Officer & Board Member | 000 0000 |
| 00000 00000000 | Self | Board Member | 000 0000 |
| 0000 00 0000000 | Self | Chairman of the Board of Directors | 000 0000 |
| 0000000 000000 | Ipsen Group | General Secretary & Board Member | 000 0000 |
Ipsen Group Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialIpsen Group Investments & Acquisitions (23)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000 00000000 | 18-Apr-2019 | 000000000000000000 | 00.000 | Biotechnology | 00000 0000 |
| 000000 (0000 00000 | 08-May-2017 | 000000000 00000 00 | 000.00 | Buildings and Property | 00000 0000 |
| 000000000 00000000 | 03-Apr-2017 | 000000000 00000 00 | 00.000 | Buildings and Property | 00000 0000 |
| 000000 00000000000 | 16-Feb-2017 | 000000000 | 0000 | Biotechnology | |
| Akkadeas Pharma | 31-Jan-2017 | Secondary Transaction - Private | Food Products |
Ipsen Group Subsidiaries (4)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Clementia Pharmaceuticals | Biotechnology | Montreal, Canada | 2010 |
| 000000 00000000000 | Drug Discovery | London, United Kingdom | 0000 |
| 00000 000000000000 | Biotechnology | Basking Ridge, NJ | 0000 |
| 00000 00000000 | Venture Capital | Boulogne Billancourt, France |
Ipsen Group Exits (6)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000 00000000000 | 16-Feb-2017 | 000000000 | 0000 | Completed |
|
| 00000 000000000000 | 13-Aug-2015 | 00000 00000 00 | 0000 | Completed |
|
| 000000 00000000000 | 13-Aug-2015 | 00000 00000 00 | 0000 | Completed |
|
| 000000 00000000000 | 29-Jul-2013 | 00000 00000 00 | 0000 | Completed |
|
| Radius Health | 16-Dec-2011 | Later Stage VC | 000.00 | Completed |
|